Sascha Tillmanns

Clinical Lead for an IL-15 superagonist in combination with CPI in advanced solid tumors: all-comers, NSCLC, mCRC, HCC, OvC, cSCC, mCRPC, phase I FiH, phase II PoC studies, clinical development plans, TPP, line manager medical team

Clinical Program Leader for an anti-CD19 antibody in hemato-oncology, clinical development stragety strategy, phase 2, registrational phase 3, real-world evidence, BLA, MAA, FDA, EMA scientific advice, due dilligence, lymphoma advisory board, clinical development plans, target product profile, study protocols, reports

Clinical development strategy, clinical trials, receptor protein, EMA regulatory agencies briefing books, scientific advice, IMPD, ODD, publication, safety narratives, multiple sclerosis, infectious diseases, inflammatory disease

Representing Clinical Development in the Program Innovation Team, Receptor Protein, Fc-gamma RIIB Antibodies, Leading Clinical Subteam for SLE and IgAN Development, Responsible for Clinical Development Plan, Investigator's Brochure, Indication Strategy, Clinical Science, Orphan Drug Designations, Protocols, Study Reports, FDA/EMA Briefing Documents, Response to Deficiency Letters, KOL, DSMB and Clinical Expert Management,

Head of Clinical Development and Preclinical Safety. Successful Acquisition of SuppreMol by Baxalta Inc for 200 Mio EUR. Responsible for the Clinical- and Nonclinical Development Strategy for a Novel Biopharmaceutical Mode of Action in the Treatment of Autoimmune Diseases, ITP, SLE, Clinical Due Diligence, Writing of Study Protocols, IBs, Orphan Drug Designation-, FDA Briefing Documents and Response to Deficiency Letters, Clinical Expert- and DSMB Management, Line Management

Head of Clinical Development and Preclinical Safety. Evaluation of Clinical Programs and Development Partners for Early Aerosol Products for Infectious Diseases and Transplantation with Focus on Orphan Drug Designation, Medical Database Research, Supervision of All Clinical Trial Activities from Phase I-III and PMS Studies

Supervisor for Clinical Project Manager in the Infectious Disease Indication, Member of Clinical Development Team, Evaluation of Clinical Programs for New Anti-infective Agents